Literature DB >> 33980628

Osteoporosis in postmenopausal women.

Samantha Moe1, Allison Paige2, G Michael Allan3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33980628      PMCID： PMC8115964          DOI： 10.46747/cfp.6705346

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  9 in total

1.  Bisphosphonates: forever or 5 years and stop?

Authors:  Michael R Kolber; Cheryl A Sadowski; Christina Korownyk
Journal:  Can Fam Physician       Date:  2015-05       Impact factor: 3.275

2.  Who should receive bone mineral density testing?

Authors:  Christina Korownyk; James McCormack; G Michael Allan
Journal:  Can Fam Physician       Date:  2015-07       Impact factor: 3.275

Review 3.  A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Authors:  M Stevenson; M Lloyd Jones; E De Nigris; N Brewer; S Davis; J Oakley
Journal:  Health Technol Assess       Date:  2005-06       Impact factor: 4.014

4.  Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Chao Wang
Journal:  Am J Ther       Date:  2017 Sep/Oct       Impact factor: 2.688

Review 5.  Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.

Authors:  Ana Julissa Serrano; Leire Begoña; Eduardo Anitua; Raquel Cobos; Gorka Orive
Journal:  Gynecol Endocrinol       Date:  2013-09-25       Impact factor: 2.260

6.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

Review 7.  Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 8.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

9.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.

Authors:  Dennis M Black; Erik J Geiger; Richard Eastell; Eric Vittinghoff; Bonnie H Li; Denison S Ryan; Richard M Dell; Annette L Adams
Journal:  N Engl J Med       Date:  2020-08-20       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.